Rigel Pharmaceuticals Inc
A South San Francisco biotechnology company that develops and sells prescription medicines for blood disorders and cancer. Its FDA-approved drugs include Tavalisse for immune thrombocytopenia (a low blood-platelet condition) and Rezlidhia for a form of acute myeloid leukemia. Founded in 1996, the company shares its name with Rigel, a brilliant blue star in the Orion constellation whose Arabic name means "the foot of the giant."
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 13G/APassive | 8.95% | 1.67M | Aug 14, 2026 |
| Steven Boyd | 13G/APassive | 8.95% | 1.67M | Aug 14, 2026 |
| Soleus Capital Master Fund, L.P. | 13G/APassive | 9.9% | 1.84M | Aug 13, 2026 |
| Soleus Capital, LLC | 13G/APassive | 9.9% | 1.84M | Aug 13, 2026 |
| Soleus Capital Group, LLC | 13G/APassive | 9.9% | 1.84M | Aug 13, 2026 |
| Soleus Capital Management, L.P. | 13G/APassive | 9.9% | 1.84M | Aug 13, 2026 |
| Soleus GP, LLC | 13G/APassive | 9.9% | 1.84M | Aug 13, 2026 |
| Guy Levy | 13G/APassive | 9.9% | 1.84M | Aug 13, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| STATE STREET CORPORATION | 13GPassive | 6% | 1.09M | Feb 9, 2026 |